Laurus Labs Q3 net surges to ₹252 crore on 26% rise in revenue

Laurus Labs reported a sharp rise in consolidated net profit for the December quarter, with earnings jumping to ₹252 crore from the ₹92 crore a year earlier, driven by a 26% year-on-year increase in revenue to ₹1,778 crore (₹1,415 crore).

Calling it another quarter of strong operational and financial performance, Chief Financial Officer V.V. Ravi Kumar said growth was led by a robust generics business and sustained demand in CDMO small-molecule offerings. EBITDA margins stood at 27.3%, supported by continued operating leverage, while gross margins improved to 60.9% from 56.9% in the corresponding quarter of the previous fiscal.

The generics business recorded a 37% year-on-year increase in the third quarter, with revenues rising to ₹1,327 crore, driven primarily by higher antiretroviral (ARV) volumes and strong offtake in select molecules within developed markets. Revenue from the CDMO business was flat at ₹451 crore (₹448 crore) on the back of 10% lower revenue in the bio — large molecules segment at ₹43 crore. The small molecules segment revenues rose 2% to ₹408 crore.

Founder and CEO Satyanarayana Chava said “we are successfully executing on our strategy with continued advancements in important CDMO projects, ramping up new launches and strengthened leadership in antiretroviral in driving strong quarter and cumulative performance. These results confirm our full year outlook of strong revenue growth and improving margin momentum.”